Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 12;7(1):24–37. doi: 10.1038/s41551-022-00969-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a, Detection of phosphorylated ERK (pERK) in iCAR-T_CTL, DGK-dKO-iCAR-T_CTL and pCAR-T_CTL 60 min after co-culturing with irradiated SK-Hep-GPC3. One-way ANOVA with Tukey’s multiple comparisons test b, Target cell-mediated proliferation of iCAR-T_CTL and DGK-dKO-iCAR-T_CTL was determined by co-culturing with irradiated SK-Hep-GPC3 and using a standard ³H-thymidine incorporation assay at 72 h (n = 3, mean ± s.e.m.). Two-sided Student’s t-test. c, Therapeutic efficacy of iCAR-T_CTL and DGK-dKO-iCAR-T_CTL in a peritoneal ovarian cancer model, and treatment schedule of the ovarian cancer peritoneal dissemination xenograft model: NSG mice were injected intraperitoneally (i.p.) with 5 × 10⁵ KOC7c cells expressing luciferase, and from the third day after the ovarian cancer inoculation, 5 × 10⁶ iCAR-T_CTL, DGK-dKO-iCAR-T_CTL or pCAR-T_CTL were injected intraperitoneally twice a week for 2 weeks (n = 8 for each group). d, In vivo bioluminescence imaging of luciferase-labelled KOC7c in NSG mice treated with iCAR-T_CTL, DGK-dKO-iCAR-T_CTL or pCAR-T_CTL. e,f, Change in the total body flux as the total tumour volume (mean ± s.e.m.) (e) and survival (f) were evaluated at the indicated timepoints after the injection. One-way ANOVA with Tukey’s multiple comparisons test and log-rank test with Bonferroni multiple comparisons test. g, Therapeutic efficacy of iCAR-T_CTL and DGK-dKO-iCAR-T_CTL with a subcutaneous liver cancer model; treatment schedule of the liver cancer subcutaneous xenograft model. NSG mice were injected intraperitoneally with 2 × 10⁵ JHH7 cells 3 days before treatment. In total, 1 × 10⁷ iCAR-T_CTL and DGK-dKO-iCAR-T_CTL were injected intravenously on days 0 and 7. h, In vivo bioluminescence imaging of injected T cells in NSG mice treated with iCAR-T_CTL, DGK-dKO-iCAR-T_CTL. i, Total flux (photons s⁻¹) of the injected iCAR-T cells in the JHH7 tumour was quantified at the indicated timepoints (n = 8, mean ± s.e.m.). Two-sided Student’s t-test.

Source data